COMPARATIVE STUDY OF MICROALBUMINURIA AND GLYCATED HEMOGLOBIN LEVELS IN TYPE 2 DIABETIC COMPLICATIONS

Authors

  • Gunjan Kumar Mandal
  • Jyothrimayi D

Abstract

ABSTRACT
Objective: Microalbuminuria occurs when the kidney leaks a small amount of albumin into the urine or when there is an abnormally high permeability
for albumin in the renal glomerulus. Microalbuminuria is a powerful risk factor of cardiovascular disease and for the presence and severity of diabetic
retinopathy and neuropathy. The aim of this study is to compare the levels of microalbumin and glycated hemoglobin (HbA1c) levels in Type 2 diabetic
complications.
Methods: The study includes 100 patients with Type 2 diabetes mellitus visiting the diabetic out-patient department patients with complications,
such as hypertension, retinopathy, neuropathy, and cardiovascular complication, was diagnosed based on history and clinical examination and related
investigations. Microalbuminuria levels and HbA1c levels are compared in patients with complications (subjects) of Type 2 diabetes mellitus and
patients without complications.
Results: The study revealed that microalbumin levels are at a significantly higher range with high HbA1c levels in patients with complications
(p<0.05). When compared to patients without complications.
Conclusion: The study supports that strict glycemic control can prevent microalbuminuria and thereby prevent progress on to diabetic nephropathy
in patients with Type 2 diabetes mellitus.
Keywords: Microalbuminuria, Glycated hemoglobin, Diabetic complications

Downloads

Download data is not yet available.

References

REFERENCES

Prasad KD, Rajaseker P. Study of micro albuminuria as a cardiovascular

risk factor in type diabetes mellitus. Iran J Kidney Dis 2012;3(1):12-6.

Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe

NR, et al. Meta-analysis: Glycosylated hemoglobin and cardiovascular

disease in diabetes mellitus. Ann Intern Med 2004;141(6):421-31.

Powers AC. Diabetes mellitus. In: Kasper DL, Braunwald E, Fauci AS,

Hauser SL, Longo DL, Jameson JL, editors. Harrison’s Principles of

Internal Medicine. 16

ed. USA: The McGraw Hill Companies Inc.;

p. 2152-80.

th

Taylor R. Practical community screening for diabetic retinopathy

using the mobile retinal camera: Report of a 12 centre study. British

diabetic association mobile retinal screening group. Diabet Med

;13(11):946-52.

Balasubramanyam M, Rema M, Premanand C. Biochemical and

molecular mechanism of diabetic retinopathy. Curr Sci 2002;83:1507-13.

Rema M, Ponnaiya M, Mohan V. Prevalence of retinopathy in noninsulin

dependent

diabetes

mellitus

at

a

diabetes

centre

in

southern

India.

Diabetes Res Clin Pract 1996;34(4):29-36.

Rema M, Deepa R, Mohan V. Prevalence of retinopathy at diagnosis

among Type 2 diabetic patients attending a diabetic centre in South

India. Br J Ophthalmol 2000;84(9):1058-60.

Gardner TW, Aiello P. Biochemical and molecular mechanism of

diadetic. Am Acad Opthalmol Monogr 2000;14:1-18.

Root HF, Pote WH Jr, Frehner H. Triopathy of diabetes; sequence of

neuropathy, retinopathy, and nephropathy in one hundred fifty-five

patients. AMA Arch Intern Med 1954;94(6):931-41.

Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R,

et al. Diabetic neuropathies: A statement by the American Diabetes

Association. Diabetes Care 2005;28(4):956-62.

Boulton AJ, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic

neuropathies. Diabetes Care 2004;27(6):1458-86.

Thomas FP. The spectrum of diabetic neuropathy. Phys Med Rehabil

Clin N Am 2008;19(1):1-v.

Abbott CA, Carrington AL, Ashe H, Bath S, Every LC, Griffiths J, et al.

The North-West diabetes foot care study: Incidence of, and risk factors

for, new diabetic foot ulceration in a community-based patient cohort.

Diabet Med 2002;19(5):377-84.

Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H. Mortality and

causes of death in the WHO multinational study of vascular disease in

diabetes. Diabetologia 2001;44 Suppl 2:S14-21.

Cea-Calvo L, Conthe P, Gómez-Fernández P, de Alvaro F, FernándezPérez

C; Richard Investigators. Target

organ

damage and cardiovascular

complications

in

patients with

hypertension and

Type

diabetes in

Asian J Pharm Clin Res, Vol 9, Issue 2, 2016, 356-360

Mandal and Jyothrimayi

Spain: A cross-sectional study. Cardiovasc Diabetol 2006;5:23.

Palatini P, Mormino P, Mos L, Mazzer A, Dorigatti F, Zanata G, et al.

Micro albuminuria, renal function and development of sustained

hypertension: A longitudinal study in the early stage of hypertension.

J Hypertens 2005;23(1):175-82.

Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR,

et al. Risk factors for coronary artery disease in non-insulin dependent

diabetes mellitus: United Kingdom Prospective Diabetes Study

(UKPDS: 23). BMJ 1998;316(7134):823-8.

Bell DS. Treatment of diabetic hypertension. Diabetes Obes Metab

;11(5):433-44.

Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M,

et al. The Anglo-Scandinavian cardiac outcomes trial lipid lowering

arm: Extended observations 2 years after trial closure. Eur Heart J

;29(4):499-508.

Bouhanick B, Berrut G, Chameau AM, Hallar M, Bled F, Chevet B,

et al. Predictive value of testing random urine sample to detect micro

albuminuria in diabetic subjects during outpatient visit. Diabete Metab

;18(1):54-8.

Ruggenenti P, Remuzzi G. Nephropathy of Type 2 diabetes mellitus.

J Am Soc Nephrol 1998;9(11):2157-69.

Al Shaikh A. Prevalence of micro albuminuria in Type 2 diabetes

mellitus at a diabetic clinic in King Abdul-Aziz University Hospital.

Pak Med Sci 2007;23:223-6.

Nathan DM, Turgeon H, Regan S. Relationship between glycated

haemoglobin levels and mean glucose levels over time. Diabetologia

;50(11):2239-44.

International Expert Committee. International Expert Committee report

on the role of the A1

assay in the diagnosis of diabetes. Diabetes Care

;32(7):1327-34.

C

Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ; AcDerived

Average

Glucose

Study

Group. Translating

the

A1

assay into

estimated average glucose values. Diabetes Care 2008;31(8):1473-8.

American Diabetes Association. Cardiovascular risk factor and disease

management in Type 2 diabetes with diabetes nephropathy. Diabetes

Care 2006;29(3):498-503.

Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG; DEMAND

Investigators. Prevalence and risk factors for micro albuminuria in

a referred cohort of Type 2 diabetic patients: A global perspective.

Kidney Int 2006;69(11):2057-63.

Gupta DK, Verma LK, Khosla PK, Dash SC. The prevalence of micro

albuminuria in diabetes: A study from north India. Diabetes Res Clin

Pract 1991;12(2):125-8.

Singh SK, Behre A, Singh MK. Diabetic retinopathy and micro

albuminuria in lean Type 2 diabetes mellitus. J Assoc Physicians India

C

;49:439-41.

Mohan V, Meera R, Premalatha G, Deepa R, Miranda P, Rema M.

Frequency of proteinuria in Type 2 diabetes mellitus seen at a diabetes

centre in Southern India. Postgrad Med J 2000;76(899):569-73.

Klein R, Klein BE, Moss SE. Prevalence of micro albuminuria in olderonset

diabetes. Diabetes Care 1993;16(10):1325-30.

Haffner SM, Morales PA, Gruber MK, Hazuda HP, Stern MP.

Cardiovascular risk factors in non-insulin-dependent diabetic subjects

with micro albuminuria. Arterioscler Thromb 1993;13(2):205-10.

John L, Rao PS, Kanagasabapathy AS. Prevalence of diabetic

nephropathy in non-insulin dependent diabetics. Indian J Med Res

;94:24-9.

Florkowski CM, Jennings PE, Rowe B, Lawson N, Nightingale S,

Barnett AH. Micro albuminuria in diabetic subjects with chronic

peripheral neuropathy. Diabetes Res Clin Pract 1988;5(1):45-8.

Parving HH, Hommel E, Mathiesen E, Skøtt P, Edsberg B, Bahnsen M,

et al. Prevalence of micro albuminuria, arterial hypertension, retinopathy

and neuropathy in patients with insulin dependent diabetes. Br Med J

(Clin Res Ed) 1988;296(6616):156-60.

Young RJ, Maclntyre CC, Martyn CN, Prescott RJ, Ewing DJ,

Smith AF, et al. Progression subclinical polyneuropathy in young

patients with - Type 1 (insulin-dependent) diabetes: Associations with

glycemic control and microangiopathy (microvascular complications).

Diabetologia 1969;29:156-61.

Bigazzi R, Bianchi S. Micro albuminuria as a marker of cardiovascular

and renal disease in essential hypertension. Nephrol Dial Transplant

;10 Suppl 6:10-4.

Pontremoli R. Micro albuminuria in essential hypertension – its

relation to cardiovascular risk factors. Nephrol Dial Transplant

;11(11):2113-5.

Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A,

et al. Prevalence and clinical correlates of micro albuminuria in

essential hypertension: The magic study. Micro albuminuria: A genoa

investigation on complications. Hypertension 1997;30(5):1135-43.

Schmitz A. Micro albuminuria, blood pressure, metabolic control, and

renal involvement: Longitudinal studies in white non-insulin-dependent

diabetic patients. Am J Hypertens 1997;10:189S-97.

Stehouwer CD, Lambert J, Donker AJ, van Hinsbergh VW. Endothelial

dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res

;34(1):55-68.

Bakris GL. Micro albuminuria: Prognostic implications. Curr Opin

Nephrol Hypertens 1996;5(3):219-23.

Mogyorósi A, Ziyadeh FN. Update on pathogenesis, markers and

management of diabetic nephropathy. Curr Opin Nephrol Hypertens

;5(3):243-53.

Published

01-03-2016

How to Cite

Mandal, G. K., and J. D. “COMPARATIVE STUDY OF MICROALBUMINURIA AND GLYCATED HEMOGLOBIN LEVELS IN TYPE 2 DIABETIC COMPLICATIONS”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 2, Mar. 2016, pp. 356-60, https://journals.innovareacademics.in/index.php/ajpcr/article/view/10920.

Issue

Section

Original Article(s)